ICCM revenueFY2025$3.38M
- FY YoY
- +2.7%
- 5Y CAGR
- -2.7%
ICCM revenue was $3.38M for fiscal 2025 (ended Dec 31, 2025), up 2.7% from fiscal 2024. Compound annual growth was -2.7% over 5 years. It rose in 5 of the last 6 fiscal years.
IceCure Medical Ltd. (ICCM) financials
For fiscal 2025 (ended Dec 31, 2025), IceCure Medical Ltd. reported $3.38M of revenue and -$15.06M of net income.
- Revenue, FY2025
- $3.38M
- Revenue growth, YoY
- +2.7%
- Net income, FY2025
- -$15.06M
- Net margin
- -445.6%
- Free cash flow, FY2025
- -$14.61M
- EPS, diluted, FY2025
- $0.24
- EPS growth, YoY
- -20.0%
- Cash
- $8.90M
- Total debt
- $13.0K
- P/S
- 0.84
- Market cap
- $2.8M
FY2019FY2025
FY2019FY2025
FY2019FY2025
ICCM revenue and earnings growth
ICCM net incomeFY2025-$15.06M
ICCM net income was -$15.06M for fiscal 2025 (ended Dec 31, 2025), compared with -$15.32M in fiscal 2024.
ICCM EPSFY2025$0.24
- FY YoY
- -20.0%
ICCM diluted EPS was $0.24 for fiscal 2025 (ended Dec 31, 2025), down 20.0% from fiscal 2024.
ICCM free cash flowFY2025-$14.61M
ICCM free cash flow was -$14.61M for fiscal 2025 (ended Dec 31, 2025), compared with -$12.63M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $3.38M | $3.29M | $3.23M | $3.08M | $4.14M | $3.87M | $1.63M |
| Cost of revenue | $2.15M | $1.84M | $1.93M | $1.64M | $1.94M | $1.42M | $1.10M |
| Gross profit | $1.23M | $1.45M | $1.30M | $1.45M | $2.19M | $2.44M | $524.0K |
| Research and development | $7.43M | $7.10M | $8.27M | $9.12M | $5.88M | $3.81M | $3.00M |
| Selling, general and admin | $4.53M | $3.75M | $4.17M | $5.86M | $4.13M | $120.0K | $1.27M |
| Operating income | -$15.09M | -$15.70M | -$15.58M | -$16.74M | -$9.72M | -$4.14M | -$4.78M |
| Net income | -$15.06M | -$15.32M | -$14.65M | -$16.98M | -$9.89M | -$3.73M | -$4.55M |
| EPS, basic | $0.24 | $0.30 | $0.32 | $0.46 | $0.35 | $0.22 | $0.33 |
| EPS, diluted | $0.24 | $0.30 | $0.32 | $0.46 | $0.35 | $0.22 | $0.33 |
| Diluted shares | 63.6M | 50.9M | 45.6M | 37.0M | 28.5M | 17.1M | 13.6M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $8.90M | $7.56M | $10.53M | $23.66M | $25.62M | $3.50M | $5.79M |
| Short-term investments | - | - | $529.0K | - | - | - | - |
| Receivables | $331.0K | $221.0K | $103.0K | $78.0K | $456.0K | $94.0K | - |
| Inventory | $2.63M | $1.99M | $2.27M | $2.86M | $1.96M | $1.06M | - |
| Current assets | $12.61M | $10.75M | $14.18M | $28.13M | $30.32M | $9.59M | - |
| Total assets | $13.89M | $12.58M | $16.41M | $30.19M | $32.28M | $10.24M | - |
| Current liabilities | $4.82M | $5.51M | $3.87M | $4.34M | $4.02M | $3.71M | - |
| Long-term debt | $13.0K | $161.0K | - | - | - | - | - |
| Total debt | $13.0K | $161.0K | - | - | - | - | - |
| Total liabilities | - | - | - | - | $5.32M | $4.59M | - |
| Shareholders' equity | $9.05M | $6.90M | $12.16M | $25.42M | $26.96M | $5.65M | $3.29M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$14.57M | -$12.56M | -$12.55M | -$14.29M | -$12.61M | -$3.69M | -$1.99M |
| Capital expenditures | $36.0K | $71.0K | $480.0K | $891.0K | $533.0K | $223.0K | $103.0K |
| Free cash flow | -$14.61M | -$12.63M | -$13.03M | -$15.18M | -$13.14M | -$3.91M | -$2.09M |
| Investing cash flow | -$36.0K | $446.0K | -$684.0K | -$891.0K | $3.79M | -$4.67M | -$103.0K |
| Financing cash flow | $15.83M | $9.19M | $83.0K | $13.58M | $30.89M | $5.86M | $3.31M |
| Stock-based compensation | $1.37M | $869.0K | $1.31M | $1.86M | $316.0K | $229.0K | $372.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 2.7% | 1.9% | 4.7% | -25.4% | 7.0% | 137.7% | - |
| EPS growth, YoY | -20.0% | -6.3% | -30.4% | 31.4% | - | -33.3% | - |
| Gross margin | 36.3% | 44.1% | 40.3% | 46.8% | 53.0% | 63.2% | 32.2% |
| Operating margin | -446.7% | -476.9% | -482.4% | -542.6% | -235.0% | -107.1% | -294.0% |
| Net margin | -445.6% | -465.5% | -453.8% | -550.3% | -239.1% | -96.4% | -279.7% |
| Free cash flow margin | -432.4% | -383.9% | -403.5% | -492.2% | -317.5% | -101.2% | -128.6% |
| Return on equity | -166.4% | -222.0% | -120.5% | -66.8% | -36.7% | -66.0% | -138.3% |
| Return on assets | -108.4% | -121.8% | -89.3% | -56.2% | -30.7% | -36.4% | - |
| Current ratio | 2.61 | 1.95 | 3.66 | 6.49 | 7.54 | 2.58 | - |
| Debt to equity | 0.00 | 0.02 | - | - | - | - | - |
Source: XBRL data IceCure Medical Ltd. files with the SEC, latest filing dated Mar 17, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
ICCM peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ICCM | $3.38M | +2.7% | -$15.06M | -445.6% | $2.8M |
| SYK | $26.30B | +7.9% | $3.62B | 13.8% | $124.00B |
| MMM | $25.25B | +1.7% | $3.54B | 14.0% | $97.47B |
| BSX | $21.07B | +8.9% | $3.50B | 16.6% | $63.81B |
| BDX | $23.25B | +17.4% | $941.00M | 4.0% | $58.63B |
| MDLN | $30.68B | - | $683.00M | 2.2% | $53.55B |
| RMD | $5.73B | +9.0% | $1.59B | 27.8% | $33.16B |
| DXCM | $5.10B | +13.0% | $991.00M | 19.4% | $30.24B |
| WST | $3.40B | +12.6% | $638.90M | 18.8% | $28.78B |
ICCM FAQ
9 questionsWhat is ICCM revenue?
IceCure Medical Ltd. (ICCM) reported $3.38M of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 2.7% from the year before.Is ICCM profitable?
No. IceCure Medical Ltd. reported a net loss of $15.06M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does ICCM have?
IceCure Medical Ltd. reported $8.90M in cash and cash equivalents and $13.0K of debt on its most recent balance sheet in SEC filings.How fast is ICCM revenue growing?
IceCure Medical Ltd.'s revenue changed +2.7% in fiscal 2025, to $3.38M. Its compound annual growth rate was -2.7% over 5 years.What is ICCM gross margin?
IceCure Medical Ltd.'s gross profit was $1.23M on $3.38M of revenue for fiscal 2025 (ended Dec 31, 2025), a gross margin of 36.3%.What is ICCM free cash flow?
IceCure Medical Ltd. generated -$14.61M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$14.57M less capital expenditures.What is ICCM earnings per share?
Diluted earnings per share were $0.24 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did ICCM last report financial results?
The latest statements here come from IceCure Medical Ltd.'s 20-F filed on Mar 17, 2026, covering the period ended Dec 31, 2025.Where does this ICCM financial data come from?
Quantisnow builds these statements from the structured XBRL data IceCure Medical Ltd. files with the SEC. It is provided for information only and is not investment advice.